Phaseline

Companies › Chengdu Suncadia Medicine

Chengdu Suncadia Medicine: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 2 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Genitourinary, Hematology, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HRS-5965
FD inhibitor (Factor D inhibitor)
–Phase 3Primary IgA Nephropathy; Paroxysmal Nocturnal HemoglobinuriaOct 2027
HRS-5765–Phase 1Heart FailureDec 2026
HRS-1635–Phase 1B-cell MalignancyOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07551167HRS-5765Phase 1Heart FailureCardiovascularDec 2026
NCT07014826HRS-5965Phase 3Primary IgA NephropathyGenitourinaryOct 2027
NCT06238544HRS-5965Phase 2Paroxysmal Nocturnal HemoglobinuriaHematologyDec 2027
NCT07583212HRS-1635Phase 1B-cell MalignancyOncologyOct 2028
NCT07582133HRS-5965Phase 2Primary IgA NephropathyGenitourinaryJul 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Kind Pharmaceuticals Biocity Biopharmaceutics Iperboreal Pharma Srl Apellis Pharmaceuticals Shenzhen Kangzhe Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.